Britannia
Senior Member
- Reaction score
- 3
This is only my THEORY, it isnt fact:
I have been trying to come up with a theory why GSK decided against proceeding with phase III trials of Dutasteride for male pattern baldness. I know there are many theories out there, so heres what I concluded. GSK must have spent large sums of cash getting through the first 2 phases of trials. It really wouldnt make any sense fianacially to back out effectively at the last minute. There is little doubt in my mind that Dutasteride would be much more efficent in combating hair loss and promoting hair regrowth, and I cannot see any reason why side effects would be an issue. I believe that sales of Propecia worldwide have been very disappointing for Merck and Im sure that companies such as Cipla producing their own generics has severely dented theyre profit margins. In fact I believe generic medications for hair loss will really begin to take off, mainly because Cipla are becoming world-renouned for producing top quality drugs at prices at a fraction of western pharmaceutical giants. In fact many of the large drug manufactorers (I better not name any specifcally) have had a real sweat on about Cipla taking the African AIDS market from them. To put it another way, Merck did the research and put the cash behind developing Propecia, only to have their product copied and produced at a price considerably lower which could mean Merck having problems recouping money they had put into researching Propecia.
Now take GSK, if they wanted to market dutasteride for hairloss they would have to change the strength/formulation to make the new drug different from Avodart, simply so they could charge more and recoup the cash they spent on research in the same way Merck charge more for Propecia than Proscar. But if you look on many online pharmacies, there are already generic dutasterides available at considerably less than the cost of Avodart. Assuming GSK did produce a drug containing hairloss containing Dutasteride they would find themselves with a HUGE gap in prices between generics and their own branded drug. And with generic medication becoming more and more popular, there really is little incentive for big drug companies to pour money into researching new medication for male pattern baldness because they simply will not be able to recoup their intial outlay.
P.S. I do not work for/recommend Cipla
P.P.S. If you read this and feel sorry for Merck/GSK please dont, they are money grabing scum who are exploiting the sick and taking advantage of the governments of countries with widespread disease and little money to pay for treatments.
I have been trying to come up with a theory why GSK decided against proceeding with phase III trials of Dutasteride for male pattern baldness. I know there are many theories out there, so heres what I concluded. GSK must have spent large sums of cash getting through the first 2 phases of trials. It really wouldnt make any sense fianacially to back out effectively at the last minute. There is little doubt in my mind that Dutasteride would be much more efficent in combating hair loss and promoting hair regrowth, and I cannot see any reason why side effects would be an issue. I believe that sales of Propecia worldwide have been very disappointing for Merck and Im sure that companies such as Cipla producing their own generics has severely dented theyre profit margins. In fact I believe generic medications for hair loss will really begin to take off, mainly because Cipla are becoming world-renouned for producing top quality drugs at prices at a fraction of western pharmaceutical giants. In fact many of the large drug manufactorers (I better not name any specifcally) have had a real sweat on about Cipla taking the African AIDS market from them. To put it another way, Merck did the research and put the cash behind developing Propecia, only to have their product copied and produced at a price considerably lower which could mean Merck having problems recouping money they had put into researching Propecia.
Now take GSK, if they wanted to market dutasteride for hairloss they would have to change the strength/formulation to make the new drug different from Avodart, simply so they could charge more and recoup the cash they spent on research in the same way Merck charge more for Propecia than Proscar. But if you look on many online pharmacies, there are already generic dutasterides available at considerably less than the cost of Avodart. Assuming GSK did produce a drug containing hairloss containing Dutasteride they would find themselves with a HUGE gap in prices between generics and their own branded drug. And with generic medication becoming more and more popular, there really is little incentive for big drug companies to pour money into researching new medication for male pattern baldness because they simply will not be able to recoup their intial outlay.
P.S. I do not work for/recommend Cipla
P.P.S. If you read this and feel sorry for Merck/GSK please dont, they are money grabing scum who are exploiting the sick and taking advantage of the governments of countries with widespread disease and little money to pay for treatments.